What Sciety does

Sciety is a Stockholm-based, privately held Nordic investment firm founded in 2014 that focuses exclusively on healthcare and life sciences. The firm operates with 11-50 employees under a founder-led management team (CEO Andreas Lindblom, CFO/COO Malin Lindblom, corporate finance directors Dawid Myslinski and Håkan Lampa) and a small functional staff covering marketing, IT, and project management. Its investment activity centers on leading or participating in financing rounds for Swedish and Nordic biotech, healthtech, and medical technology companies across verticals including precision diagnostics, personalized cancer immunotherapy, digital primary care, pharmaceutical manufacturing tools, and drone-based emergency healthcare.

Sciety's underlying technology is essentially its investment management platform and sector knowledge rather than a licensable product; the proprietary advantage lies in deal sourcing, diligence, and follow-on support within Nordic life sciences. The firm has reached its tenth portfolio exit via the Foundation Medicine (Roche subsidiary) agreement to acquire Saga Diagnostics for up to USD 595 million, marking a milestone in its precision diagnostics thesis. Visible recent deployments include a SEK 87 million round into Neogap Therapeutics, a SEK 40 million round into Hälsa Hemma, a SEK 36 million round into Everdrone, and a EUR 3.9 million investment in PeptiSystems (later co-invested by Rubicon Healthcare Partners).

The business model is investment-driven: Sciety earns revenue primarily through equity returns on portfolio companies, with deal-flow originating from direct Nordic industry networks and co-investor relationships. Go-to-market is enterprise-style direct investment into portfolio companies rather than traditional B2B sales, and pricing/contract structures are not publicly disclosed. There are no disclosed enterprise customers, marketing channels, or product integrations at the firm level, and the company's headquarters remains its principal operating base in Stockholm.

Name

Sciety

Website

https://sciety.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Sciety is a Stockholm-based Nordic investment firm founded in 2014 that leads financing rounds in Swedish and Nordic healthcare and life sciences companies across biotech, healthtech, and medical technology, and has reached ten portfolio exits including Saga Diagnostics to Roche.

Ownership category

akta.pro rank

Product category

Venture Capital / Private Equity (Healthcare Focus)

NAICS

Portfolio Management and Investment Advice (52394), Other Financial Investment Activities (5239)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Venture capital services
• Healthcare investment
• Life sciences funding
• Private equity
• Growth capital

Headquarters

HQ city

Stockholm

HQ country

Sweden

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Investment Returns: Sciety generates returns through equity investments in healthcare and life sciences companies, with exits such as the Saga Diagnostics acquisition by Foundation Medicine (Roche subsidiary) for up to USD 595 million, representing their tenth exit.

Go-to-market motion1 record

Core offering

Sciety is a Nordic investment company that deploys venture and growth capital into healthcare and life sciences companies, primarily across the Nordics. The firm invests in early- and growth-stage businesses in areas such as medical devices, digital health, biotechnology, and related healthcare innovation, generating returns through equity ownership, investment income, and transaction-based exits.

Product overview

Sciety is a Nordic investment company that focuses on investing in healthcare and life science companies. The company does not offer a technology product or service in the traditional SaaS sense; rather, it operates as an investment firm that builds and manages a portfolio of healthtech, biotech, and medical technology companies.

Differentiator

Problem solved

Functional benefit

Products and services

• Healthcare and Life Sciences Venture & Growth Capital Equity capital provided to Nordic healthcare and life sciences companies across early- and growth-stage rounds; intended for founders, management teams, and boards of privately held healthcare companies (including medical devices, digital health, and biotechnology) seeking specialized sector investment.

Quantifiable outcome

• 10th exit achieved through Saga Diagnostics acquisition by Foundation Medicine/Roche for up to USD 595 million
• +1 more outcomes

Segments5 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Direct peers

• Industrifonden: Industrifonden (now renamed Saminvest) is a Nordic venture and growth capital investor with significant healthcare and life sciences exposure, backing Swedish and Scandinavian companies. Comparable to Sciety as a Swedish-rooted growth investor participating in similar financing rounds and sectors.
• Kurma Partners: Kurma Partners is a European healthcare-focused venture capital firm investing in biotech and digital health across Europe. Directly comparable to Sciety as a healthcare-dedicated European VC targeting therapeutics, diagnostics, and healthtech opportunities.
• Medicxi: Medicxi is a European life sciences-focused investment firm backing asset-centric biotech and specialty pharma companies. Comparable to Sciety as a European healthcare investor focused on therapeutics development, though operating across broader European geographies.
• Roslin Capital: Roslin Capital is a Scottish/Nordic-connected life sciences investor backing early-stage biotech and medtech companies. Comparable to Sciety as a Northern European healthcare specialist investor targeting similar company stages.
• Atlas Venture: Atlas Venture is a biotech-focused early-stage venture capital firm creating and building breakthrough therapeutics companies. Comparable to Sciety as a sector-specialized biotech investor with a thesis-driven company-creation approach, though primarily US-focused rather than Nordic.
• HealthCap: HealthCap is a Nordic venture capital firm focused exclusively on healthcare and life sciences, investing in therapeutics, medical devices, and diagnostics. Directly comparable to Sciety as a sector-specialized Nordic healthcare investor with multiple funds and a long exit track record.
• Novo Holdings (Novo Seeds): Novo Holdings' Novo Seeds program is a Nordic life sciences venture investor backing early-stage biotech, medtech, and diagnostics companies across Scandinavia. Directly comparable as a Nordic healthcare specialist investor with deep sector expertise and an active portfolio similar to Sciety's.
• Forbion: Forbion is a European venture capital firm focused on life sciences and biotech, investing across therapeutics and diagnostics. Directly comparable to Sciety as a healthcare-dedicated VC with a pan-European footprint, though at a larger scale than Sciety.
• Sunstone Capital: Sunstone Capital is a Danish/Nordic venture capital firm with a dedicated life sciences practice backing biotech and medtech companies in the region. Directly comparable to Sciety as a Nordic-focused healthcare investor targeting similar company stages and verticals.

Broad incumbents

• EQT Life Sciences: EQT Life Sciences (formerly LSP) is the dedicated life sciences arm of EQT, a major European private equity firm, investing in biotech, medtech, and diagnostics across Europe. Comparable to Sciety as a larger, well-established healthcare investor operating in the same geographies and asset classes but at materially greater scale.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments43 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sciety